Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene
| Data(s) |
13/10/2016
13/10/2016
04/10/2016
|
|---|---|
| Resumo |
Tamoxifen (TAM) has been widely used to treat estrogen receptor (ER)-positive breast cancer, and has led to reduction of 50% in the annual recurrence rate and 30% in breast cancer mortality after 5 years of treatment.1 The prodrug TAM is a selective ER modulator that antagonizes ERs in cancer cells. However, compared with its two active metabolites 4-hydroxy-TAM (4-OH-TAM) and endoxifen, it is a relatively weak antiestrogen. SIN FINANCIACIÓN 3.784 JCR (2015) Q1, 52/255 Pharmacology & pharmacy; Q2, 47/166, Genetics & heredity UEM |
| Identificador |
Novillo, A., Romero-Lorca, A., Gaibar, M., Rubio, M., & Fernández-Santander, A. (2016). Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene. The Pharmacogenomics Journal. DOI: 10.1038/tpj.2016.73 1470269X 14731150 http://hdl.handle.net/11268/5867 10.1038/tpj.2016.73 |
| Idioma(s) |
eng |
| Direitos |
openAccess |
| Palavras-Chave | #Tamoxifeno #Mamas - Cáncer #Cáncer |
| Tipo |
article |
